

Pilot phase IV, multicenter, randomized, open-label and controlled study to assess the evolution of peripheral body fat distribution after switching from zidovudine-containing backbone to truvada in HIV-1-infected patients on highly active antiretroviral therapy

Submission date 23/01/2006	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 11/04/2006	Overall study status Completed	☐ Protocol
Last Edited 13/07/2015	Condition category Infections and Infestations	☐ Statistical analysis plan
		☐ Results
		☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Esteban Ribera Pascuet

Contact details
Hospital Vall d'Hebrón
Passeig de Vall D'Hebrón, 119-129
Barcelona
Spain
08035

Additional identifiers

Protocol serial number
GS-ES-164-0154

Study information

Scientific Title

Pilot phase IV, multicenter, randomized, open-label and controlled study to assess the evolution of peripheral body fat distribution after switching from zidovudine-containing backbone to truvada in HIV-1-infected patients on highly active antiretroviral therapy

Acronym

RECOMB

Study objectives

Eligible patients must have been on zidovudine (AZT) treatment for at least six months. The rationale for this criterion is that it has been widely described that after this period of time, sub-clinical body fat changes can be developed, related to alterations in mitochondrial function and replication capacity of the subcutaneous adipose tissue. These changes could lead to an objective lipoatrophy (loss of 20% of peripheral fat) several months later. To assess the potential benefit of switching to truvada is the main objective for this study. Another objective of this study is to evaluate the changes in body fat distribution as measured by dual-energy x-ray absorptiometry (DEXA) after switching from AZT-containing backbone to truvada

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics Committee of the Hospital Vall d'Hebron, Barcelona, Spain, 10/03/2006

Primary study design

Interventional

Study design

Pilot phase IV multicenter open-labelled randomized controlled study

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Human immunodeficiency virus (HIV)

Interventions

Patients on current HAART regimen containing zidovudine and lamivudine at usual doses for at least six months, will be randomised to switch to truvada (fixed-dose combination of tenofovir and emtricitabine) or to continue with the same HAART regimen containing zidovudine and lamivudine. The other drugs included in the original HAART regimen will not change.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Zidovudine, lamivudine, truvada (fixed-dose combination of tenofovir and emtricitabine)

Primary outcome(s)

Objective assessment of change from baseline in limb fat at week 48 as measured by DEXA

1. Dual-energy x-ray absorptiometry (DEXA) scans will be performed at baseline, week 24, week 48 and week 72
2. Study of mitochondrial toxicity at baseline, week 12, week 24, week 48 and week 72

Key secondary outcome(s)

1. Change in the mitochondrial deoxyribonucleic acid (DNA) or nuclear DNA ratio in the different visits compared with baseline
2. Change in lactate concentration in the different visits compared with baseline
3. Proportion of patients who maintain confirmed HIV-1 RNA levels of <50 copies per ml
4. Proportion of patients with HIV-1 RNA levels between >50 and <400 copies per ml
5. Proportion of patients with virologic failure as confirmed by two consecutive HIV-1 RNA >400 copies/ml
6. Time to loss of virological response, defined as the time elapsed from the patient's first dose of study drug to confirmed HIV-1 RNA levels of >50 and <400 copies/ml, death caused by the disease, medication discontinuation, or addition of a new antiretroviral medication
7. Time to definite virological failure, defined as the time elapsed from the patient's first dose of study drug to confirmed HIV-1 RNA levels of >400 copies/ml
8. Change in CD4+ cell counts in the different study visits compared with baseline
9. Change in serum triglycerides, total cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) fractions in the different study visits compared with baseline
10. Change in hemoglobin and hematocrit concentrations in the different visits compared with baseline
11. Proportion of patients with different specific mutations after virological failure
12. Proportion of patients who show treatment adherence

Completion date

12/12/2007

Eligibility**Key inclusion criteria**

1. Human immunodeficiency virus (HIV-1) infection as documented by positively confirmed HIV-1 antibody test and/or positive polymerase chain reaction (PCR) for HIV-1 ribonucleic acid (RNA)
2. Adult patients (over 18 years of age)
3. Currently on highly active antiretroviral therapy (HAART) regimen, containing zidovudine and lamivudine at usual doses for at least six months
4. Viral load <50 copies/ml on the last two consecutive determinations under zidovudine and lamivudine-containing HAART regimen
5. For women of childbearing potential, negative urine pregnancy test at screening visit
6. Agreement to take part in the study and signed informed consent form
7. Patients on lipid-lowering treatment will be allowed to participate in the study only if the lipid-lowering treatment (either statins or fibrates) is stable for at least eight weeks prior to screening and is not expected to change this treatment during the first three months of the trial

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

1. Patients on current transdermal fentanyl (TDF) or emtricitabine (FTC) therapy
2. Patients with a previous history of virological failure on FTC or TDF-containing regimen
3. Patients receiving a non-registered antiretroviral (ARV) drug
4. Patients receiving a triple nucleoside-ARV combination
5. Hypersensitivity to one of the components of the dosage forms of TDF or FTC, or previous history of intolerance to one of these drugs
6. Known history of drug abuse or chronic alcohol consumption
7. Women who are pregnant or breast-feeding or females of childbearing potential who do not use an adequate method of contraception according to the investigator's judgment
8. Current active opportunistic infection or documented infection within the previous four weeks
9. Documented active malignant disease (excluding Kaposi's sarcoma limited to the skin)
10. Renal disease with creatinine clearance <50 ml/min
11. Concomitant use of nephrotoxic or immuno-suppressive drugs, which cannot be stopped without affecting the safety of the patient
12. Receiving on-going therapy with systemic corticosteroids, interleukin-2 (IL-2) or chemotherapy
13. Patients not to be included in the study according to the investigator's criterion

Date of first enrolment

05/04/2006

Date of final enrolment

12/12/2007

Locations

Countries of recruitment

Spain

Study participating centre

Hospital Vall d'Hebrón

Barcelona

Spain

08035

Sponsor information

Organisation

Gilead Sciences, SL (Spain)

ROR

<https://ror.org/02qacef07>

Funder(s)

Funder type

Industry

Funder Name

Gilead Sciences, SL

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration